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ABSTRACT  
 
α-Methylacyl-CoA racemase (AMACR; P504S) catalyses an essential step in the degradation of branched-chain 
fatty acids and the activation of ibuprofen and related drugs. AMACR has gained much attention as a drug target 
and biomarker, since it is found at elevated levels in prostate cancer and several other cancers. Herein, we report 
the synthesis of 2-(phenylthio)propanoyl-CoA derivatives which provided potent AMACR inhibitory activity (IC50 = 
22–100 nM), as measured by the AMACR colorimetric activity assay. Inhibitor potency positively cor-relates with 
calculated logP, although 2-(3-benzyloxyphenylthio)propanoyl-CoA and 2-(4-(2-methylpropoxy) 
phenylthio)propanoyl-CoA were more potent than predicted by this parameter. Subsequently, carboxylic acid 
precursors were evaluated against androgen-dependent LnCaP prostate cancer cells and androgen-independent 
Du145 and PC3 prostate cancer cells using the MTS assay. All tested precursor acids showed inhibitory activity 
against LnCaP, Du145 and PC3 cells at 500 µM, but lacked activity at 100 µM. This is the first extensive structure-
activity relationship study on the influence of side-chain interactions on the potency of novel rationally designed 
AMACR inhibitors.  
 
 
1. Introduction 
 
Branched-chain fatty acids, e.g. phytanic and pristanic acids, are 
common components of the human diet [1–3]. Degradation of these 
fatty acids occurs as the corresponding acyl-CoA, initially within per-
oxisomes and subsequently within mitochondria [3,4]. Phytanic acid 
possesses a 3-methyl group, which hinders degradation by β-oxidation 
[1–4]. Therefore, initial metabolism is via the α-oxidation pathway, 
resulting in the formation of pristanic acid, which possesses a 2-methyl 
group, which is subsequently converted into pristanoyl-CoA. The ste-
reochemical configuration of chiral centres in phytanic acid are re-
tained in the α-oxidation pathway [3] and this means that R-2- 
 
 
 
methylacyl-CoAs are generated. Oxidation of cholesterol to bile acids 
also results in the formation of R-2-methylacyl-CoAs (with the chiral 
centre at carbon-25 in the standard numbering system for bile acids) 
[1,2]. The acyl-CoA oxidases catalysing the first step in the β-oxidation 
degradative pathway requires S-2-methylacyl-CoAs [5–7] and cannot 
accept R-2-methylacyl-CoAs. This means that 2R-pristanoyl-CoA, its β-
oxidation pathway products and the acyl-CoA derivatives of bile acids 
cannot be directly metabolized by β-oxidation.  
The enzyme α-methylacyl-CoA racemase (AMACR; P504S; E.C. 
5.1.99.4) catalyses conversion of these R-2-methylacyl-CoAs to S-2-
methylacyl-CoAs, thus enabling β-oxidation. The reaction appears to 
occur by a deprotonation/reprotonation mechanism [8–10], probably 
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through an enolate intermediate [11], and a near 1:1 mixture of S- and 
R-2-methylacyl-CoA epimers is produced (‘racemization’) [9,10,12]. 
The resulting S-2-methylacyl-CoAs are degraded by β-oxidation [1–4], 
while the resulting R-2-methylacyl-CoAs are further metabolized to 
their S-epimers by AMACR, thus ensuring complete metabolism. In 
addition to its role in fatty acid metabolism, AMACR is also involved in 
the irreversible pathway which converts R-ibuprofen to S-ibuprofen via 
the corresponding acyl-CoA esters [1,2,10]. As only the S-enantiomer 
of ibuprofen is a potent inhibitor of cyclooxygenases-1 and -2 [13], this 
pathway results in the pharmacological activation of the inactive R-
ibuprofen. Several other ‘profens’ also undergo similar R- to S-conver-
sion in humans and other mammals [1,2,10]. AMACR has also been 
claimed to be involved in the S- to R- conversion of mandelic acid in 
mammalian cells [14], but this role was subsequently disproved [15].  
There has been increased attention towards targeting AMACR as a 
chemotherapeutic strategy to combat prostate cancer (PCa). AMACR 
activity is increased by 4- to 10-fold in clinical prostate cancer tissue 
samples, compared with the corresponding normal tissue [16,17]. 
Many spliced variants of AMACR have been reported [18–21], with the 
most highly expressed spliced variant, AMACR 1A, demonstrated to 
have ‘racemase’ activity [9,12]. Several other spliced variants of 
AMACR are predicted not to possess racemase activity, as they lack 
key catalytic residues or a C-terminal dimerization domain [1,2,18–21]. 
Knockdown of AMACR 1A significantly reduces the proliferation of 
several androgen-dependent (AD) [17,22] and androgen-independent 
(AI) [23] PCa cell lines at similar levels to that observed for the current 
standard of care (androgen-deprivation) or androgen-receptor (AR) 
antagonists (Casodex) [17]. Additionally, knock-down of AMACR has 
shown to revert advanced PCa cells from AI to AD status by post-
transcriptional upregulation of the AR [23]. Many investigations, e.g. 
Takahara et al. [23], demonstrate that AMACR is over-expressed at 
significantly higher levels in AI PCa cells compared to AD PCa cells, 
which has stimulated great interest in exploring AMACR as a PCa bio-
marker [1,24–27] and drug target [22,24,28–33]. Inhibitors of AMACR 
could be exploited as mono-therapeutic agents or used in combination 
with androgen-deprivation therapy to target CRPC [17,23].  
Most previously reported AMACR inhibitors have been developed 
using rational design, based on substrate structures and the enzyme 
catalytic mechanism [24,28–30,33]. Inhibitors of the M. tuberculosis 
homologue enzyme (MtMCR), for which X-ray crystal structures have 
been solved [8,11,34], include the gem-disubstituted substrate-product 
analogues 2,2-bis(4-(2-methylpropyl)lphenyl)propanoyl-CoA and 2,2-
bis(4-tert-butylphenyl)propanoyl-CoA, which inhibit MtMCR with Ki 
values of 16.9 ± 0.6 and 21 ± 4 µM, respectively [32]. Carbamate 
analogues of these inhibitors have recently been reported to be irre-
versible inhibitors of MtMCR [31]. However, until recently, there has 
been no convenient assay to measure AMACR activity or evaluate the 
potency of inhibitors, and this has hampered inhibitor development 
[35,36]. We recently developed a continuous assay which is 
convenient to use for inhibitor characterization, using a chromogenic 
substrate which produces the intensely yellow 2,4-dinitrophenolate 
anion upon incubation with AMACR [30,36].  
Herein, we report the synthesis of a panel of novel 2-ar-
ylthiopropanoyl-CoA derivatives (‘thiolactate inhibitors’). These in-
hibitors were tested in vitro against human AMACR 1A in the first 
systematic examination of rational inhibitor side-chain interactions and 
their influence on inhibitor potency. We then examined selected ex-
amples of the carboxylic acid precursors of these inhibitors against a 
panel of AD- and AI-PCa cell lines to evaluate their potential as treat-
ments for prostate cancer. 
 
2. Results and discussion 
 
2.1. Rational design of inhibitors 
 
The X-ray crystal structure of mammalian AMACR has not been 
 
 
reported to date; however, numerous structures of ligands bound to the M. 
tuberculosis homologue (MtMCR) [8,11] reveal the binding mode of several 
known substrates/inhibitors. There is 43% sequence identity between 
MtMCR and AMACR 1A [22] (Supplementary Information, Fig. S1), 
including residues comprising active site catalytic bases, residues binding 
to the CoA moiety, and other active site residues. Therefore, structural 
information can be used to help design rational inhibitors of  
AMACR.  
These MtMCR structures suggest that AMACR 1A contains a well-
defined binding site for the CoA moiety, which is lined by cationic ar-ginine 
and lysine residues binding to the phosphate groups. The methyl group is 
thought to bind in a well-defined pocket, and this hypothesis is supported by 
the observation that the presence of an α-methyl group  
[30] (or similar group [29]) enhances inhibition of AMACR, compared 
to corresponding analogues that contain a hydrogen atom at the same 
position. Similarly, biochemical studies show that 2-methylacyl-CoA 
substrates are better substrates than those lacking the α-methyl group  
[37]. The α-carbon of the 2-methylacyl-CoA substrate is positioned so 
that the active site bases (His-122/Glu-241 and Asp-152; numbering 
refers to human AMACR 1A) are located either side of the α-carbon in 
order to perform the deprotonation/reprotonation reaction effectively. 
Two overlapping side-chain binding sites, termed the R- and S-pockets, 
accommodate substrate/inhibitor side-chains and this probably ac-
counts for the observed differences in potency between different epi-
mers of 2-methylacyl-CoA-like inhibitors [28]. This led to the design of 
gem-disubstituted substrate-product analogues, which are thought to 
inhibit MtMCR by simultaneous binding of side-chains to both the R-and 
S-binding sites [31].  
Previous work on AMACR have attempted to develop inhibitors by 
increasing the acidity of the α-proton [28] or by mimicking the planar enolate 
intermediate [24,29,30,36]. The first inhibitors with highly acidic α-protons 
contained fluorine [28] but these were subsequently shown to be substrates 
which eliminate HF and form the corresponding unsaturated analogue 
[12,30,35]. We therefore decided to prepare a focused set of 2-
arylthiopropanoyl-CoA analogues (‘thiolactate in-hibitors’), in the 
expectation that these would form stabilized enolates which would bind 
tightly to AMACR. Previous work on 3-thia analo-gues of straight-chain acyl-
CoA oxidase substrates confirm a diminution of the pKa of the α-proton by 
ca. 5 units [38–41] (∼16 for 3-thiaoc-tanoyl-CoA vs. ∼ 21 for octanoyl-CoA 
[38]), supporting this approach.  
The target compounds were synthesized as epimeric mixtures at 
the 2-position, as formation of the enolate and loss of stereochemical 
con-figuration was anticipated to be facile. In parallel, we also 
investigated the corresponding sulfone analogues, reasoning that the 
sulfone group would promote formation of the enolate even more 
strongly, potentially resulting in even more potent inhibition. 
Fenoprofenoyl-CoA 1 pro-vided the starting side-chain structure, as 
this was previously shown to be the best of the series of substrates 
with aromatic side-chains [10] and is a known inhibitor [30]. 
 
2.2. Synthesis of inhibitors 
 
Synthesis of initially designed inhibitors used the reaction of 3- or 4-
phenoxybenzenethiol 1 with ethyl ( ± )-2-bromopropanoate to afford 
the ethyl esters 2 (Scheme 1). The required phenoxybenzenethiols 1 
have been synthesized from the corresponding phenoxyphenols 3 by 
treatment with dimethylthiocarbamoyl chloride [42] to give 4. A 
Newman-Kwart thermal rearrangement was subsequently used to pro-
vide the required carbamothioate 5. Only low levels of conversion were 
observed at 260 °C [43], while extensive decomposition occurred at 
300 °C. A compromise temperature of 280 °C gave the required 
product in moderate yield whilst minimizing decomposition. Hydrolysis 
of 5 furnished the required phenoxybenzenethiols 1 but these rapidly 
oxi-dized to the corresponding disulfides so they were treated with 
ethyl ± 2-bromopropanoate without purification. The resulting esters2 
were hydrolyzed to the acids 6, which were activated with N,N′- 
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Scheme 1. Synthesis of 2-arylthiopropanoyl-CoAs 7 and 2-arylsulfonylpropanoyl-CoAs 10. a: R
1
 = PhO, R
2
 = H; b: R
1
 = H, R
2
 = PhO. Reagents and conditions: i. 
dimethylthiocarbamoyl chloride, DMF, ii. Δ; iii. NaOH, H2O, MeOH; iv. K2CO3, ethyl ( ± )-2-bromopropanoate, MeCN; iv. CDI, CH2Cl2; v. CoA-Li
+
3, NaHCO3, H2O, THF; 
vi. OXONE®, H2O. Note that no product was obtained for 10a. 
 
carbonyl diimidazole and converted into their corresponding acyl-CoA 
esters 7 [10,12,30,36,44].  
Synthesis of the sulfone analogues was achieved by oxidation of 
the ethyl ester intermediate 2 (Scheme 1). OXONE® treatment [45] of 
2 resulted in formation of the sulfone ethyl esters 8 in ca. 80% yield, 
which were subsequently hydrolyzed to the acids 9 with aqueous base 
in high yield. Conversion of the 3-substituted-acid 9a to the corre-
sponding acyl-CoA 10a was attempted using the standard carbonyl 
diimidazole method [10,12,30,36,44] but this did not result in the 
desired product. This failure may be due to the low nucleophilicity of 
the carboxylate anion of 9a, as further experiments showed low yields 
of the intermediate acyl-imidazole. Alternatively, formation of the en-
olate may be facile under the conditions used to make the acyl-CoA 
and this results in side-reactions or depletion of base resulting in low 
levels of the required imidazole intermediate. Similarly, use of a mixed 
an-hydride method [9,24] did not give 10a and starting material was re-
covered. Activation of the isomeric carboxylic acid 9b with carbonyl 
diimidazole and coupling with reduced CoA [10,12,30,36,44] resulted 
in formation of the corresponding acyl-CoA ester 10b in low yield.  
Preparation of further 2-arylthiopropanoyl-CoA derivatives 7c-o 
(Scheme 2) began with selective alkylation of a mercaptophenol 11 
with ethyl ( ± )-2-bromopropanoate to provide the corresponding ethyl ( 
± )-2-(hydroxyphenylthio)propanoates 12. Alkylation of the phenolic 
oxygen of 12 with benzyl or alkyl bromide derivatives provided a series 
of substituted benzyloxy or alkoxy esters 2c-o. Hydrolyses of the 
esters revealed the corresponding carboxylic acids 6c-o, which were 
con-verted into their CoA esters 7c-o using N,N′-carbonyl diimidazole. 
 
2.3. Evaluation of compounds in vitro 
 
Initially compounds 7a and 7b were tested using our deuterium-
exchange assay [9,10] (Supporting information, Fig. S2). Significant 
exchange of 7a/7b α-1H for α-2H was observed in negative controls 
containing heat-inactivated AMACR, showing that formation of the 
enolate occurred rapidly. In the case of the 3-substituted isomer, 7a ca. 
70% exchange was observed in the absence of active AMACR. 
Incuba-tion in the presence of active AMACR resulted in even greater 
levels of exchange for the 4-substituted isomer 7b, indicating that this 
com-pound was a substrate. In the case of the 3-substituted isomer 7a, 
limited further exchange was observed against the high non-enzymatic 
background levels showing that it was also a substrate.  
Inhibition of AMACR activity was subsequently evaluated using our 
colorimetric assay [30,36]. Initial evaluation showed that 7a and 7b 
were moderately potent inhibitors, with IC50 values of 247 nM and 354 
nM, respectively. Fenoprofenoyl-CoA 1 showed an IC50 value of 340 
nM (consistent with the literature report of 400 nM [30]). Thus, both 
phenoxy-phenylthiopropanoyl-CoAs 7a and 7b were inhibitors of 
comparable potency to fenoprofenoyl-CoA 1. In contrast, the 4-phe-
noxyphenylsulfone analogue 10b showed an IC50 value of ca. 46 µM, 
showing a highly significant decrease in potency compared to 1. This 
 
diminution in inhibitory activity was unexpected, as 10b was expected 
to undergo exchange of the α-proton even more readily than the thia 
analogues and hence was predicted to bind to AMACR even more 
tightly. This loss of inhibitory activity correlates with a reduction in 
lipophilicity [46] (Table 1, Fig. 1, Supporting Information Fig. S4), 
suggesting that potency is largely driven by side-chain interactions ra-
ther than formation of the enolate. Further experiments showed that all 
three inhibitors gave rise to rapidly reversible inhibition (Supporting 
Information).  
The further series of 3- and 4-substituted 2-arylthiopropanoyl-CoAs 7c-
o were then tested as inhibitors of AMACR activity (Table 1). As expected, 
potency was generally correlated with drug (side-chain) li-pophilicity, 
although there were exceptions (Fig. 1 and Supporting Information Figs. S3 
and S4). This is consistent with the proposed model in which the inhibitor 
side-chain binds to the methionine-rich surface (‘side-chain binding site’), 
as observed in the X-ray crystal structures [8] of ligands bound to the M. 
tuberculosis homologue, MCR. 
In the 3-substituted series, the most potent inhibition was observed 
for the benzyl derivative 7c (IC50 = 22.3 nM) and this was far more 
potent than expected based on calculated lipophilicity (Fig. S3). Addi-
tion of a 3-MeO group to the benzyl to give 7d decreased potency to 
the level predicted by the lipophilicity. Extending the side-chain with a 
further CH2- group in 7e did not make a significant difference in po-
tency, compared to 7d. Addition of a MeO- group to the terminal aro-
matic ring in 7f gave a small improvement in potency. However, the 
expected increase in potency upon addition of a lipophilic tri-
fluoromethyl- group was not observed and 7g had a similar level of 
potency as 7f (Fig. S3). Compound 7h, substituted with a 3-(2-me-
thylpropoxy) group, was less potent, as expected based on lipophilicity 
calculations.  
In contrast, substitutions at the 4-position gave potent inhibition for 
almost all derivatives. Extension of the linker from 7b (no CH2- groups) 
to  7i  (one  CH2- group) resulted  in an increase  in potency 
(IC50 = 354 nM vs. 113 nM). Addition of a MeO-group to the terminal 
aromatic  ring in 7j  made a  small  difference  to  the potency 
(IC50 = 71 nM vs. 113 nM]. Analogue 7k had  similar potency 
[IC50 = 99 nM vs. 113 nM] to 7i, showing that increasing the linker by a 
further CH2 group did not have a significant effect, as observed for the 
corresponding regioisomers. Substitution of the terminal phenyl ring  
with a MeO- group in 7l or with a CF3 group in 7m gave similar levels 
of inhibitory potency, again showing that inhibitor potency was not in-
creased as much as expected upon introduction of the lipophilic tri-
fluoromethyl- group. 4-Substitution with an aliphatic pentoxyl chain also 
resulted in potent inhibition, as shown by 7n with an IC50 value of 90 
nM, consistent with predictions based on lipophilicity. Surprisingly, 
substitution with the smaller 2-methylpropoxy- group in 7o gave five-
fold more potent inhibition than in the 3-substituted analogue 7h (IC50 
= 106 nM vs. 522 nM).  
As expected, activity in the presence of inhibitors was reversed 
upon rapid dilution, showing reversible inhibition for all compounds 
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Scheme 2. Synthesis of further 2-arylthiopropanoyl-CoAs 7c-o designed as inhibitors of AMACR. Reagents and conditions: i, ethyl ( ± )-2-bromopropanoate, CHCl3, 
NEt3; ii, R-Br, DMF, K2CO3 or R-OH, THF, PPh3, DIAD; iii, NaOH, H2O, MeOH; iv, CDI, CH2Cl2; v CoA-Li
+
3, NaHCO3, H2O, THF. 
 
(Supporting information). Kinetic analysis using varying substrate 
concentrations in the presence or absence of 22.5 nM 7c was used to 
determine the mode of inhibition. This analysis showed that mixed 
competitive inhibition was the most likely kinetic mode of action, with 
ationKi).value of 14.6 ± 2.0 nM (mean ± S.E.M.) (Supporting informa- 
 
2.4. Cellular evaluation of compounds 
 
Inhibitors of AMACR have been evaluated as their carboxylic acid 
precursors at the cellular level because of the poor cell permeability, the 
hydrolytic instability of the acyl-CoAs, and the known facile acyl-CoA 
formation from carboxylate inhibitor precursors in cells [24,28]. Therefore, 
the carboxylic acid precursors (6c,h-j,n,o) were tested against AD (LnCaP) 
and AI (Du145 and PC3) prostate cancer cell lines. The selected 
compounds were chosen as the corresponding acyl-CoA esters 
represented a range of 3- and 4-substituted derivatives (7c,h-j,n,o) with the 
inhibitors giving a range of activities, including the most potent (7c). 
Fenoprofen was included as a positive control.  
These compounds were initially screened at 500 µM, 200 µM and 
100 µM against the three cell lines. The 2-arylthiopropanoic acids 6 
provided strong anti-proliferative activity (33–88%; Supporting 
Information, Table S1) against all three prostate cancer cell lines at 
500 µM, and moderate activity at 200 µM. However, no significant 
 
activity was observed at 100 µM. ‘Unusual’ fatty acids and derivatives 
are generally taken up into cells with subsequent import into peroxi-
somes as their acyl-CoA esters for metabolism and detoxification[1,4]; it 
was therefore anticipated that 6 would be taken up into cells (as has 
been shown for other AMACR inhibitor precursors [24]) and co-localize 
with AMACR in peroxisomes and mitochondria [47,48]. Conversion of 
the carboxylic acid into the acyl-CoA ester to produce the drug was 
expected to take place. It appears that 6 are not converted efficiently 
into 7, and that this is responsible for the observed lack of activity. It is 
also possible that inhibitors 7 are removed by rapid metabolism, but 
previous work on 3-thia acyl-CoAs have suggested this is not the case 
[38,41,49]. 
 
3. Conclusions 
 
Development of the 2-arylthiapropanoyl-CoA (‘thiolactate’) series of 
inhibitors demonstrates that highly potent inhibition of AMACR can be 
achieved in vitro. The structure-activity relationships can be largely 
predicted based on lipophilicity calculations, although there are ex-
amples where inhibitors of both higher and lower potency than ex-
pected have been produced, which results from side-chain interactions 
with the enzyme [8]. Although the inhibitor precursors failed to sig-
nificantly inhibit growth of prostate cancer cells, the study demon-
strates the potential for development of rationally-designed drugs 
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Table 1  
IC50 values for inhibitor acyl-CoAs 1, 7a-o, 10b, as measured by the colorimetric assay [36], and the calculated lipophilicity (calc. LogP). IC50 values are expressed as 
geometric means for three independent repeats with lower and upper geometric Standard Error of the Mean values in parentheses (see Experimental for details). 
a
Only 
one IC50 determination was performed for this compound due to the low synthetic yield of the acyl-CoA. 
b
LogP values calculated using http://www. 
molinspiration.com/cgi-bin/properties.  
 
 
 
 
Fenoprofenoyl-CoA 1 7a - n  10b    
Compound R
1 R2 IC50 (nM) Calc. logP
b 
1 – – 340 (282, 408) −3.77 
7a PhO H 247 (217, 281) −3.95 
7b H PhO 354 (324, 379) −3.93 
7c BnO H 22.3 (20.1, 24.7) −4.05 
7d 3-MeOBnO H 420 (399, 442) −4.00 
7e Ph(CH2)2O H 437 (423, 452) −3.85 
7f 3-MeOPh(CH2)2O H 294 (267, 322) −3.81 
7g 3-F3CPh(CH2)2O H 313 (301, 325) −2.97 
7h Me2CHCH2O H 520 (492, 549) −4.42 
7i H BnO 113 (103, 124) −4.03 
7j H 3-MeOBnO 133 (120, 147) −4.00 
7k H Ph(CH2)2O 99 (93, 106) −3.82 
7l H 3-MeOPh(CH2)2O 71 (69, 73) −3.79 
7m H 3-F3CPh(CH2)2O 51 (46, 56) −2.95 
7n H Me(CH2)4O 90 (80, 100) −3.68 
7o H Me2CHCH2O 105 (95, 115) −4.41 
10b H PhO 4.6 × 10
4 a 
−4.91 
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Fig. 1. Lipophilicity of 2-arylthiopropanoyl-CoA inhibitors 7a-o, sulfone 10b and 
fenoprofenoyl-CoA 1. Log10 IC50 values are reported ± 1 SD. Calculated LogP 
used in this Figure are presented in Table 1. Compounds in green are more 
potent than expected, and compounds in red are less potent than expected 
based on calculated lipophilicity. 
 
targeting AMACR. 
 
4. Materials and methods 
 
4.1. Sources of materials 
 
Reagents were purchased from the Sigma-Aldrich Chemical Co., 
Fisher Scientific or Fluorochem. Reduced coenzyme A, tri-lithium salt 
was purchased from Calbiochem. Deuterated solvents were purchased 
from Goss Scientific. Anhydrous and general grade solvents were pur-
chased from the Sigma-Aldrich Chemical Co. and used without further 
purification. Water for aqueous solutions was obtained from a 
Nanopure Diamond system (18.2 MΩ.cm−1). Human recombinant 
AMACR 1A was expressed and purified and colorimetric substrate 
synthesized as previously described [36]. Fenoprofenoyl-CoA 1 was 
 
synthesized as previously described [10]. 
 
 
4.2. General experimental procedures 
 
Syntheses were carried out at ambient temperature, unless other-
wise specified. Solutions in organic solvents were dried with MgSO4. 
Thin layer chromatography was performed on Merck silica aluminium 
plates 60 (F254) and visualized with UV light, potassium 
permanganate or phosphomolybdic acid. Column chromatography was 
performed using Fisher silica gel (particle size 35–70 µm). Purification 
of acyl-CoA esters was performed by solid-phase extraction using 
Oasis HLB 6 cc (200 mg) extraction cartridges. Columns were 
conditioned with acet-onitrile and water. After loading the columns 
were eluted with water, 10%, 25% and 50% of MeCN in water (v/v). 
NMR spectra were re-corded at 22 °C at 400.04 or 500.13 MHz (1H) 
and 100.59 or 125.76 MHz (13C) on Bruker Avance III NMR 
spectrometers in D2O or CDCl3. 1H NMR spectra recorded for known 
compounds matched data reported in the literature unless otherwise 
stated. Mass spectra were recorded on an ESI-TOF instrument. High 
resolution mass spectra were recorded in ES mode. Acyl-CoA esters 
were characterized by 1 H NMR and HRMS. Compounds 1a [50], 1b 
[43], and 12b [45] were synthe-sized by known literature methods. 
Compound 5b was synthesized by the literature method [43] except 
that the temperature was increased to 280 °C.  
Aqueous solutions for biological experiments were prepared in 
Nanopure water of 18.2 MΩ.cm−1 quality and were pH-adjusted with 
aq. HCl or NaOH. The pH of aqueous solutions was measured using a 
Corning 240 pH meter and Corning general purpose combination 
electrode. The pH meter was calibrated using Fisher Chemicals stan-
dard buffer solutions (pH 4.0 - phthalate, 7.0 - phosphate, and 10.0 - 
borate) at either pH 7.0 and 10.0 or 7.0 and 4.0. Calibration and 
measurements were carried out at ambient room temperature. Stock 
concentrations of acyl-CoA esters for assays were determined using 
1H NMR. 
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4.3. Synthesis of compounds 
 
4.3.1. Ethyl ( ± )-2-(4-phenoxyphenylthio)propanoate (2b)  
Anhydrous K2CO3 (367 mg, 2.65 mmol) was stirred with 4-phe-
noxybenzenethiol 1b (534 mg, 2.64 mmol) in dry MeCN (4.9 mL) at 
−45 °C for 15 min. MeCN (1.8 mL) was added, followed by ethyl ( ± )-
2-bromopropanoate (0.35 mL, 2.64 mmol) in MeCN (1.2 mL). The 
mixture was warmed to 20 °C and stirred for 20 h. Filtration (Celite®), 
evaporation and chromatography (PE/EtOAc 30:1) afforded 2b (630 
mg, 79%) as a colourless oil. IR νmax/cm−1 1731 (C]O); 1H NMR 
(400.04 MHz, CDCl3): δ 7.44 (2H, d, J = 8.8 Hz), 7.37–7.31 (2H, m), 
7.13 (1H, tt, J = 7.3, 1.1 Hz), 7.04–6.98 (2H, m), 6.93 (2H, d, J = 8.8 
Hz), 4.18–4.07 (2H, m), 3.68 (1H, q, J = 7.1 Hz), 1.45 (3H, d, J = 7.1 
Hz) and 1.20 (3H, t, J = 7.1 Hz); δ (100.59 MHz, CDCl3) 172.47, 
157.97, 156.30, 135.91, 129.76, 126.09, 123.75, 119.31,  
118.61, 60.98, 45.69, 17.13 and 13.99; ESI–MS m/z 325.0991 [M + 
Na]+ (C17H18NaO3S requires 325.0869). Compound 2b was 
hydrolyzed to the corresponding acid using General Method C and 
converted into the acyl-CoA ester by General Method D. 
Spectroscopic data are available in the Supporting Information. 
 
4.3.2. O-(3-Phenoxyphenyl) N,N-dimethylthiocarbamate (4a)  
NaH (60% w/w dispersion in oil, 1.20 g, 30.0 mmol) was added 
slowly 3–phenoxyphenol 3a (1.86 g, 10.0 mmol) in dry DMF (27 mL) at 
10 °C. N,N-dimethylthiocarbamoyl chloride (5.78 g, 46.8 mmol) was 
added after evolution of H2 had ceased. The mixture was stirred at 70 
°C for 21 h and then cooled to ambient temperature. Water (100 mL) 
was added and the mixture was extracted thrice with CHCl3. The 
organic layers were combined, washed with aq. KOH (0.89 M, 50 mL) 
and brine. Drying, evaporation and chromatography (PE/EtOAc 5:1) 
afforded 4a (1.86 g, 68%) as a colourless oil. IR νmax/cm−1 1139 
(C]S); 1H NMR (400.04 MHz, CDCl3): δ 7.38–7.30 (3H, m), 7.15–7.05 
(3H, m), 6.93 (1H, ddd, J = 8.3, 2.4, 1.0 Hz), 6.86 (1H, ddd, J = 8.1, 
2.2, 1.0 Hz), 6.78 (1H, t, J = 2.2 Hz), 3.41 (3H, s), 3.26 (3H, s); δ 
(100.59 MHz, CDCl3) 185.78, 157.41, 156.11, 154.50, 129.43, 129.31, 
123.26, 118.76, 117.08, 115.53, 113.15, 42.76, 38.27; ESI-MS m/z 
274.0900 [M + H]+ (C15H16NO2S requires 274.0902). 
 
4.3.3. S-3-Phenoxyphenyl-N,N-dimethylcarbamothioate (5a)  
Compound 4a (1.76 g, 6.43 mmol) was heated at 280 °C under Ar 
for 100 min. Chromatography (PE/EtOAc 19:1 → 3:1) gave 5a (664 
mg, 38%) as a brown oil. IR νmax/cm−1 1671 (C]O); δ (400.04 MHz, 
CDCl3) 7.39–7.30 (3H, m), 7.29–7.24 (1H, m), 7.20 (1H, dd, J = 2.2, 
1.7 Hz), 7.13 (1H, tt, J = 8.4, 1.1 Hz), 7.09–7.01 (3H, m) and 3.03 (6H, 
br s); δ (100.59 MHz; CDCl3) 166.01, 157.09, 156.46, 130.10, 129.98, 
129.63, 129.59, 125.37, 123.32, 119.14, 118.91, 36.60; ESI-MS m/z  
274.0879 [M + H]+ (C15H16NO2S requires 274.0902). 
 
4.3.4. Ethyl ( ± )-2-(3-phenoxyphenylthio)propanoate (2a).  
Compound 5a was prepared from 3–phenoxybenzenethiol 1a  
(94 mg, 0.47 mmol), using the procedure as for compound 5b, to afford 
a colourless oil (94 mg, 67%). IR νmax/cm−1 1732 (C]O); 1H NMR 
(400.04 MHz, CDCl3): δ 7.38–7.30 (2H, m), 7.25 (1H, t, J = 8.0 Hz), 
7.20–7.07 (3H, m), 7.04–6.97 (2H, m), 6.94–6.89 (1H, m), 4.15–4.03 
(2H, m), 3.78 (1H, q, J = 7.2 Hz), 1.48 (3H, d, J = 7.2 Hz) and 1.17 
(3H, t, J = 7.2 Hz); δ (100.59 MHz; CDCl3) 172.38, 157.44, 156.59, 
135.02, 129.88, 129.75, 126.95, 123.54, 122.24, 119.01, 118.04, 
61.17, 44.94, 17.29 and 13.97; ESI-MS m/z 325.0868 [M + Na]+ 
(C17H18NaO3S requires 325.0874). 
 
4.3.5. Ethyl ( ± )-2-(3-phenoxyphenylsulfonyl)propanoate (8a)  
A solution of OXONE® (470 mg, excess) in water (4.7 mL) was added to 
2a (115 mg, 0.38 mmol) in MeOH/THF (1:1, 4.7 mL) and the mixture was 
stirred for 4 h. The mixture was filtered (Celite®). Water was added to the 
evaporation residue, which was extracted thrice with EtOAc. Drying, 
evaporation and chromatography (PE/EtOAc 20:1 → 3:1) gave 
 
 
8a (123 mg, 97%) as a colourless oil (> 95% pure by 1H NMR), which 
was used in the next step without further purification. IR νmax/cm−1 
1738 (C]O), 1326, 1139 (S]O); δ (500.13 MHz, CDCl3) 7.58 (1H, dt, J = 
7.5, 1.1 Hz), 7.51 (1H, t, J = 8.1 Hz), 7.46 (1H, t, J = 2.0 Hz), 7.38 (2H, 
tt, J = 7.5, 2.0 Hz), 7.28 (1H, ddd, J = 8.2, 2.3, 1.0), 7.18 (1H, tt, J = 
7.4, 0.9 Hz), 7.03 (2H, d, J = 8.0 Hz), 4.10 (2H, q, J = 7.3 Hz), 4.02 
(1H, q, J = 7.3 Hz), 1.55 (3H, d, J = 7.3 Hz) and 1.17 (3H, t, J = 7.3 
Hz); δ (125.76 MHz; CDCl3) 165.96, 158.04, 155.65, 138.37, 130.34, 
130.10, 124.52, 123.86, 123.42, 119.48, 118.53, 65.31, 62.21, 13.78 
and 11.63; ESI-MS m/z 333.0799 [M - H]- (C17H17O5S requires 
333.0797). 
 
4.3.6. Ethyl ( ± )-2-(4-phenoxyphenylsulfonyl)propanoate (8b) 
Compound 2b (143 mg. 0.47 mmol) was treated with OXONE®, as 
for 8a, to give 8b (129 mg, 82%) as a colourless oil. IR νmax/cm−1 
1738 (C]O), 1324, 1144 (S]O); 1H NMR (400.04 MHz, CDCl3): δ 7.81 
(2H, d, J = 9.0 Hz), 7.45–7.37 (2H, m), 7.23 (1H, tt, J = 7.4, 1.1 Hz), 
7.10–7.02 (4H, m), 4.14 (2H, q, J = 7.2 Hz), 4.02 (1H, q, J = 7.1 Hz, 
CH), 1.55 (3H, d, J = 7.1 Hz), 1.20 (3H, t, J = 7.2 Hz); δ (100.59 MHz, 
CDCl3) 166.33, 162.94, 154.63, 131.66, 130.20, 130.02, 125.22, 
120.45, 117.13, 65.44, 62.13, 13.82 and 11.90; ESI-MS m/z 333.0807 
[M - H]- (C17H17O5S requires 333.0797). 
 
4.3.7. Ethyl ( ± )-2-(3-hydroxyphenylthio)propanoate (12a)  
3-Hydroxythiophenol 11a (3.00 g, 23.8 mmol) and ethyl 2-bromo-  
propanoate (3.1 mL, 24 mmol) were stirred at reflux in CHCl3 (80 mL) 
with NEt3 (5.0 mL, 36 mmol) for 1 h. The cooled mixture was washed 
with water and brine. Drying, evaporation and chromatography gave 
12a (4.65 g, 86%) as a yellow oil. 1H NMR (400.04 MHz, CDCl3): δ 
7.16 (1H, t, J = 8.0 Hz), 7.00 (1H, ddd, J = 7.8, 1.8, 1.0 Hz), 6.95 (1H, 
ddd, J = 2.5, 1.7, 0.4 Hz), 6.75 (1H, ddd, J = 8.2, 2.5, 1.0 Hz), 5.46 
(1H, br s), 4.20–4.08 (2H, m), 3.81 (1H, q, J = 7.1 Hz), 1.50 (3H, d, J = 
7.1 Hz), 1.20 (3H, t, J = 7.1 Hz). 13C NMR (100.59 MHz, CDCl3) δ 
173.07, 155.89, 134.67, 129.90, 124.70, 119.23, 115.08, 61.42, 45.16, 
17.36, 13.99. ESI-MS m/z 249.0577 [M + Na]+ (C11H14NaO3S re-quires 
249.0556). 
 
4.3.8. General method A: Synthesis of compounds 2c, d, h, i, j, n and o 
Compounds 12a or 12b, in DMF (15 mL), was stirred at 100 °C with K2CO3 
(1.22 g, 8.84 mmol) and the appropriate alkyl bromide [benzyl bromide 
(0.32 mL; 2c and 2i), 3-methoxybenzyl bromide (0.32 mL or 0.37 mL; 2d 
and 2j), 1-bromo-2-methylpropane (0.29 mL; 2 h and 2o) or 1-
bromopentane (0.24 mL; 2n)] (2.66 mmol), for 1 h. The reaction mixture 
was cooled and the DMF was evaporated. The residue, in CH2Cl2, was 
washed twice with water and once with brine. Drying and evaporation gave 
the required compounds. Spectroscopic data for these  
compounds are given in the Supporting information. 
 
4.3.9. General method B: Synthesis of compounds 2e-g, k-m  
DIAD (0.65 mL, 3.31 mmol) was added dropwise to 12a or 12b 
(500 mg, 2.21 mmol), PPh3 (869 mg, 3.31 mmol) and appropriate al-
cohol [2-phenylethanol (0.27 mL, 2.21 mmol, 2e; or 0.17 mL, 1.46 
mmol, 2k), 2-(3-methoxyphenyl)ethanol (0.31 mL, 2.21 mmol, 2f;  
0.20 mL, 1.46 mmol, 2l), or 2-(3-trifluoromethylphenyl)ethanol (0.33 
mL, 2.21 mmol, 2g and 2m] in THF (10 mL), and the mixture was 
stirred for 18 h. Drying, evaporation and chromatography (PE/EtOAc 
20:1) gave the esters 2e-g, k-m. Spectroscopic data for these com-
pounds are given in the Supporting information. 
 
4.3.10. General method C: Hydrolysis of the ethyl ester to give compounds  
6a-o  
Aq. NaOH (2.5 M, 2.0 mL, 5.00 mmol) was stirred with of the ethyl 
ester 2a-o in MeOH (15 mL) for 1.5 h. MeOH was evaporated and the 
mixture was acidified with aq. HCl (1.0 M) to pH ∼ 3 and extracted 
twice with CH2Cl2. The combined organic layers were washed with 
brine. Drying, evaporation and chromatography (PE/EtOAc 2:1) gave 
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the carboxylic acids 6a-6o. Spectroscopic data for these compounds 
are given in the Supporting information. 
 
4.3.11. General method D: Formation of acyl-CoA esters 7a-o 
Carboxylic acids 6a-o in dry CH2Cl2 (3.0 mL) was treated with N,N′-  
carbonyl diimidazole (32 mg, 0.2 mmol) in one portion and the mixture 
was stirred for 1 h. The mixture was washed with water (5 × 2 mL) and 
brine. Drying, filtration and evaporation gave the crude imidazolide. 
This material was dissolved in THF (3.0 mL), then CoA-Li3 (31 mg, 0.04 
mmol) in aq. NaHCO3 (0.1 M, 3.0 mL) was added and the mixture was 
stirred for 18 h. The solution was acidified to pH ∼ 3 with aq. HCl (1 M) 
and the solvents were partly removed under reduced pressure. Water 
(2.0 mL) was added and the mixture was washed with EtOAc (5 × 3 
mL). Solid-phase extraction of the aqueous layer gave the re-quired 
acyl-CoA esters 7a-o. Spectroscopic data for these compounds are 
given in the Supporting Information. 
 
4.3.12. Evaluation of AMACR inhibition by test compounds in vitro 
Colorimetric assays were performed as previously described  
[30,36], except that the concentration of DMSO in the final assay was 
10% (v/v). Control experiments showed that no reduction in activity 
was observed at this concentration. Assays were conducted in full- or 
half-volume 96-well plates, in a final volume of 200 or 100 µL, re-
spectively. Control experiments have previously shown identical results 
using full and half-volume plates [30,36]. Reaction rates were de-
termined by plotting A354 with time in Excel, and data was analysed 
using SigmaPlot 13 as previously described [30,36]. Log10 IC50 values 
were calculated from individual dose-response curves with inhibition of 
binding plotted against Log10 drug concentration (in M). Mean Log10 
IC50 values were then calculated from 3 independent repeats together 
with corresponding Log10 Standard Error of the Mean (S.E.M.) values. 
Data were then converted to non-logarithmic values to produce the 
geometric mean with corresponding upper and lower limits of the 
geometric S.E.M. values (Table 1). Ki values were determined as de-
scribed using 8 concentrations of substrate (150, 100, 66.6, 29.6, 19.8, 
13.1, 8.8 and 5.9 µM in assay), in the presence of 0 or 22.5 nM 7c, and 
analysed with SigmaPlot as previously described [36]. Data are means 
± S.E.M., for 3 dependent repeats. 
 
Funding sources 
 
This work was funded by Prostate Cancer UK (S10-03 and PG14-
009), a University of Bath Overseas Research Studentship, a 
Biochemical Society Summer Vacation studentship (2016) and a 
Shandong-Bath undergraduate exchange studentship (2016). 
 
Notes 
 
The authors are members of the Cancer Research @ Bath 
(CR@B) network. 
 
Appendix A. Supplementary material 
 
Supplementary data to this article can be found online at https:// 
doi.org/10.1016/j.bioorg.2019.103263. 
 
References 
 
[1] M.D. Lloyd, D.J. Darley, A.S. Wierzbicki, M.D. Threadgill, α-Methylacyl-CoA race-
mase: An ‘obscure’ metabolic enzyme takes centre stage, FEBS J. 275 (2008) 
1089–1102. 
[2] M.D. Lloyd, M. Yevglevskis, G.L. Lee, P.J. Wood, M.D. Threadgill, T.J. 
Woodman, α-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug 
metabolizer and cancer marker P504S, Prog. Lipid Res. 52 (2013) 220–230. 
[3] M. Mukherji, C.J. Schofield, A.S. Wierzbicki, G.A. Jansen, R.J.A. Wanders,  
M.D. Lloyd, The chemical biology of branched-chain lipid metabolism, Prog. Lipid 
Res. 42 (2003) 359–376. 
[4] R.J.A. Wanders, Metabolic functions of peroxisomes in health and disease, 
 
 
Biochimie 98C (2014) 36–44.  
[5] K.P. Battaile, M. McBurney, P.P. Van Veldhoven, J. Vockley, Human long chain, 
very long chain and medium chain acyl-CoA dehydrogenases are specific for 
theS-enantiomer of 2-methylpentadecanoyl-CoA, Biochim. Biophys. Acta -Lipids 
Lipid Metabol. 1390 (1998) 333–338.  
[6] P.P. VanVeldhoven, K. Croes, S. Asselberghs, P. Herdewijn, G.P. Mannaerts, 
Peroxisomal β-oxidation of 2-methyl-branched acyl-CoA esters: Stereospecific re-
cognition of the 2S-methyl compounds by trihydroxycoprostanoyl-CoA oxidase 
and pristanoyl-CoA oxidase, FEBS Lett. 388 (1996) 80–84. 
[7] P.P. Van Veldhoven, K. Croes, M. Casteels, G.P. Mannaerts, 2-Methylacyl racemase:  
A coupled assay based on the use of pristanoyl-CoA oxidase / peroxidase and 
re-investigation of its subcellular distribution in rat and human liver, Biochim. 
Biophys. Acta-Lipids Lipid Metabolism 1347 (1997) 62–68. 
[8] P. Bhaumik, W. Schmitz, A. Hassinen, J.K. Hiltunen, E. Conzelmann, R.K. 
Wierenga, The catalysis of the 1,1-proton transfer by α-methyl-acyl-CoA 
racemase is coupled to a movement of the fatty acyl moiety over a hydrophobic, 
methionine-rich sur-face, J. Mol. Biol. 367 (2007) 1145–1161.  
[9] D.J. Darley, D.S. Butler, S.J. Prideaux, T.W. Thornton, A.D. Wilson, T.J. 
Woodman, M.D. Threadgill, M.D. Lloyd, Synthesis and use of isotope-labelled 
substrates for a mechanistic study on human α-methylacyl-CoA racemase 1A 
(AMACR; P504S), Org. Biomol. Chem. 7 (2009) 543–552. 
[10] T.J. Woodman, P.J. Wood, A.S. Thompson, T.J. Hutchings, G.R. Steel, P. Jiao, 
M.D. Threadgill, M.D. Lloyd, Chiral inversion of 2-arylpropionyl-CoA esters by α-
methylacyl-CoA racemase 1A (AMACR; P504S), Chem. Commun. 47 (2011) 
7332–7334.  
[11] S. Sharma, P. Bhaumik, W. Schmitz, R. Venkatesan, J.K. Hiltunen, E. 
Conzelmann, A.H. Juffer, R.K. Wierenga, The enolization chemistry of a 
thioester-dependent racemase: The 1.4 Å crystal structure of a reaction 
intermediate complex char-acterized by detailed QM/MM calculations, J. Phys. 
Chem. B 116 (2012) 3619–3629.  
[12] M. Yevglevskis, G.L. Lee, M.D. Threadgill, T.J. Woodman, M.D. Lloyd, The perils 
of rational design – unexpected irreversible elimination of inorganic fluoride from 
3-fluoro-2-methylacyl-CoA esters catalysed by α-methylacyl-CoA racemase 
(AMACR; P504S), Chem. Commun. 50 (2014) 14164–14166.  
[13] J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, J.R. Vane, 
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constituative and 
inducible cyclooxygenase, Proc. Natl. Acad. Sci. U.S.A 90 (1993) 11693–11697. 
[14] L.-B. Gao, J.-Z. Wang, T.-W. Yao, S. Zeng, Study on the metabolic mechanism 
of chiral inversion of S-mandelic acid in vitro, Chirality 24 (2012) 86–95. 
[15] M. Yevglevskis, C.R. Bowskill, C.C.Y. Chan, J.H.-J. Heng, M.D. Threadgill,  
T.J. Woodman, M.D. Lloyd, A study on the chiral inversion of mandelic acid in 
humans, Org. Biomol. Chem. 12 (2014) 6737–6744. 
[16] C. Kumar-Sinha, R.B. Shah, B. Laxman, S.A. Tomlins, J. Harwood, W. Schmitz,  
E. Conzelmann, M.G. Sanda, J.T. Wei, M.A. Rubin, A.M. Chinnaiyan, Elevated α-
methylacyl-CoA racemase enzymatic activity in prostate cancer, Am. J. Pathol. 
164 (2004) 787–793. 
[17] S. Zha, S. Ferdinandusse, S. Denis, R.J. Wanders, C.M. Ewing, J. Luo, A.M. De 
Marzo, W.B. Isaacs, α-Methylacyl-CoA racemase as an androgen-independent 
growth modifier in prostate cancer, Cancer Res. 63 (2003) 7365–7376. 
[18] J.N. Mubiru, G.L. Shen-Ong, A.J. Valente, D.A. Troyer, Alternative spliced 
variants of the α-methylacyl-CoA racemase gene and their expression in prostate 
cancer, Gene 327 (2004) 89–98. 
[19] J.N. Mubiru, A.J. Valente, D.A. Troyer, A variant of α-methylacyl-CoA racemase 
gene created by a deletion in exon 5 and its expression in prostate cancer, 
Prostate 65 (2005) 117–123. 
[20] G.L. Shen-Ong, Y. Feng, D.A. Troyer, Expression profiling identifies a novel α-me-
thylacyl-CoA racemase exon with fumarate hydratase homology, Cancer Res. 63 
(2003) 3296–3301. 
[21] B. Ouyang, Y.-K. Leung, V. Wang, E. Chung, L. Levin, B. Bracken, L. Cheng, S.-
M. Hi, α-Methylacyl-CoA racemase spliced variants and their expression in 
normal and malignant prostate tissues, Urology 77 (2011) e1–e7. 
[22] B.A.P. Wilson, H. Wang, B.A. Nacev, R.C. Mease, J.O. Liu, M.G. Pomper,  
W.B. Isaacs, High-throughput screen identifies novel inhibitors of cancer 
biomarker α-methylacyl-coenzyme A racemase (AMACR/P504S), Mol. Cancer 
Ther. 10 (2011) 825–838. 
[23] K. Takahara, H. Azuma, T. Sakamoto, S. Kiyama, T. Inamoto, N. Ibuki, T. Nishida,  
H. Nomi, T. Ubai, N. Segawa, Y. Katsuoka, Conversion of prostate cancer from 
hormone independency to dependency due to AMACR inhibition: Involvement of 
increased AR expression and decreased IGF1 expression, Anticancer Res. 29 
(2009) 2497–2505.  
[24] A. Morgenroth, E.A. Urusova, C. Dinger, E. Al-Momani, T. Kull, G. Glatting,  
H. Frauendorf, O. Jahn, F.M. Mottaghy, S.N. Reske, B.D. Zlatopolskiy, New mole-cular 
markers for prostate tumor imaging: A study on 2-methylene substituted fatty acids as 
new AMACR inhibitors, Chem. Eur. J. 17 (2011) 10144–10150. 
[25] Z. Jiang, B.A. Woda, K.L. Rock, Y.D. Xu, L. Savas, A. Khan, G. Pihan, F. Cai, 
J.S. Babcook, P. Rathanaswami, S.G. Reed, J.C. Xu, G.R. Fanger, P504S - A 
new molecular marker for the detection of prostate carcinoma, Am. J. Surg. 
Path. 25 (2001) 1397–1404.  
[26] X.M.J. Yang, C.L. Wu, B.A. Woda, K. Dresser, M. Tretiakova, G.R. Fanger, Z. Jiang, 
Expression of α-methylacyl-CoA racemase (P504S) in atypical adenomatous hy-
perplasia of the prostate, Am. J. Surg. Pathol. 26 (2002) 921–925. 
[27] J. Luo, S. Zha, W.R. Gage, T.A. Dunn, J.L. Hicks, C.J. Bennett, C.N. Ewing,  
E.A. Platz, S. Ferdinandusse, R.J. Wanders, J.M. Trent, W.B. Isaacs, A.M. De 
Marzo, α-Methylacyl-CoA racemase: A new molecular marker for prostate cancer, 
Cancer Res. 62 (2002) 2220–2226. 
[28] A.J. Carnell, I. Hale, S. Denis, R.J.A. Wanders, W.B. Isaacs, B.A. Wilson, 
 
7 
 
 
 
S. Ferdinandusse, Design, synthesis, and in vitro testing of α-methylacyl-CoA 
race-mase inhibitors, J. Med. Chem. 50 (2007) 2700–2707. 
[29] A.J. Carnell, R. Kirk, M. Smith, S. McKenna, L.-Y. Lian, R. Gibson, Inhibition of 
human α-methylacyl-CoA racemase (AMACR): a target for prostate cancer, 
ChemMedChem 8 (2013) 1643–1647. 
[30] M. Yevglevskis, G.L. Lee, A. Nathubhai, Y.D. Petrova, T.D. James, M.D. 
Threadgill, T.J. Woodman, M.D. Lloyd, Structure-activity relationships of rationally 
designed AMACR 1A inhibitors, Bioorg. Chem. 79 (2018) 145–154. 
[31] M. Pal, N.M. Easton, H. Yaphe, S.L. Bearne, Potent dialkyl substrate-product ana-
logue inhibitors and inactivators of α-methylacyl-coenzyme A racemase from 
Mycobacterium tuberculosis by rational design, Bioorg. Chem. 77 (2018) 640–650. 
[32] M. Pal, M. Khanal, R. Marko, S. Thirumalairajan, S.L. Bearne, Rational design and 
synthesis of substrate-product analogue inhibitors of α-methylacyl-coenzyme A 
racemase from Mycobacterium tuberculosis, Chem. Commun. 52 (2016) 2740–2743. 
[33] C. Festuccia, G.L. Gravina, A. Mancini, P. Muzi, E. Di Cesare, R. Kirk, M. Smith, 
S. Hughes, R. Gibson, L.-Y. Lian, E. Ricevuto, A.J. Carnell, Trifluoroibuprofen in-
hibits alpha-methylacyl coenzyme A racemase (AMACR/P504S), reduces 
cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate 
cancer models, Anti-Cancer Ag. Med. Chem. 14 (2014) 1031–1041.  
[34] K. Savolainen, P. Bhaumik, W. Schmitz, T.J. Kotti, E. Conzelmann, R.K. 
Wierenga, J.K. Hiltunen, α-Methylacyl-CoA racemase from Mycobacterium 
tuberculosis: Mutational and structural characterization of the active site and the 
fold, J. Biol. Chem. 280 (2005) 12611–12620.  
[35] M. Yevglevskis, G.L. Lee, J. Sun, S. Zhou, X. Sun, G. Kociok-Köhn, T.D. James, 
T.J. Woodman, M.D. Lloyd, A study on the AMACR catalysed elimination reaction 
and its application to inhibitor testing, Org. Biomol. Chem. 14 (2016) 612–622. 
[36] M. Yevglevskis, G.L. Lee, A. Nathubhai, Y.D. Petrova, T.D. James, M.D. 
Threadgill, T.J. Woodman, M.D. Lloyd, A novel colorimetric assay for α-
methylacyl-CoA ra-cemase 1A (AMACR; P504S) utilizing the elimination of 2,4-
dinitrophenolate, Chem. Commun. 53 (2017) 5087–5090.  
[37] F.A. Sattar, D.J. Darley, F. Politano, T.J. Woodman, M.D. Threadgill, M.D. Lloyd, 
Unexpected stereoselective exchange of straight-chain fatty acyl-CoA α-protons 
by human α-methylacyl-CoA racemase 1A (P504S), Chem. Commun. 46 (2010) 
3348–3350.  
[38] P. Vock, S. Engst, M. Eder, S. Ghisla, Substrate activation by acyl-CoA dehy-
drogenases: Transition-state stabilization and pKs of involved functional 
groups, Biochemistry 37 (1998) 1848–1860. 
[39] J.P. Richard, T.L. Amyes, Proton transfer at carbon, Curr. Opin. Chem. Biol. 5 
 
 
(2001) 626–633.  
[40] T.L. Amyes, J.P. Richard, Generation and stability of a simple thiol ester enolate 
in aqueous solution, J. Am. Chem. Soc. 114 (1992) 10297–10302. 
[41] R.C. Trievel, R. Wang, V.E. Anderson, C. Thorpe, The role of the carbonyl group 
in thioester chain-length recognition by the medium-chain acyl-CoA 
dehydrogenase, Biochemistry 34 (1995) 8597–8605. 
[42] M.S. Newman, H.A. Karnes, Conversion of phenols to thiophenols via dialkylthio-
carbamates, J. Org. Chem. 31 (1966) 3980–3984. 
[43] S. Brown, M.M. Bernardo, Z.H. Li, L.P. Kotra, Y. Tanaka, R. Fridman, S. 
Mobashery, Potent and selective mechanism-based inhibition of gelatinases, J. 
Am. Chem. Soc. 122 (2000) 6799–6800. 
[44] N.J. Kershaw, M. Mukherji, C.H. MacKinnon, T.D.W. Claridge, B. Odell,  
A.S. Wierzbicki, M.D. Lloyd, C.J. Schofield, Studies on phytanoyl-CoA 2-hydro-
xylase and synthesis of phytanoyl-coenzyme A, Bioorg. Med. Chem. Lett. 11 
(2001) 2545–2548. 
[45] V. Aranapakam, G.T. Grosu, J.M. Davis, B.H. Hu, J. Ellingboe, J.L. Baker,  
J.S. Skotnicki, A. Zask, J.F. DiJoseph, A. Sung, M.A. Sharr, L.M. Killar, T. Walter, 
G.X. Jin, R. Cowling, Synthesis and structure-activity relationship of α-sulfo-
nylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for 
the treatment of osteoarthritis, J. Med. Chem. 46 (2003) 2361–2375.  
[46] Z. Li, C.X. Liu, X. Xu, Q.Q. Qiu, X. Su, Y.X. Dai, J.Y. Yang, H.L. Li, W. Shi, C. Liao, M.B. 
Pan, W.L. Huang, H. Qian, Discovery of phenylsulfonyl acetic acid derivatives with 
improved efficacy and safety as potent free fatty acid receptor 1 agonists for the 
treatment of type 2 diabetes, Euro. J. Med. Chem. 138 (2017) 458–479.  
[47] L. Amery, M. Fransen, K. De Nys, G.P. Mannaerts, P.P. Van Veldhoven, Mitochondrial 
and peroxisomal targeting of 2-methylacyl-CoA racemase in humans, 
J. Lipid Res. 41 (2000) 1752–1759.  
[48] T.J. Kotti, K. Savolainen, H.M. Helander, A. Yagi, D.K. Novikov, N. Kalkkinen,  
E. Conzelmann, J.K. Hiltunen, W. Schmitz, In mouse α-methylacyl-CoA racemase, the 
same gene product is simultaneously located in mitochondria and peroxisomes, 
J. Biol. Chem. 275 (2000) 20887–20895.  
[49] S.M. Lau, R.K. Brantley, C. Thorpe, The reductive half-reaction of acyl-CoA 
dehy-drogenase from pig kidney - Studies with thiaoctanoyl-CoA and 
oxaoctanoyl-CoA analogs, Biochemistry 27 (1988) 5089–5095. 
[50] A. Gangjee, N.P. Dubash, S.F. Queener, The synthesis of new 2,4-diaminofuro 
2,3-d pyrimidines with 5-biphenyl, phenoxyphenyl and tricyclic substitutions as 
dihy-drofolate reductase inhibitors, J. Heterocyclic Chem. 37 (2000) 935–942. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
